A study conducted by Chen et al. studied PT2399 in vivo, showing activity in both tumor cell lines and patient-derived xenografts, in both treatment-naïve and Sunitinib-resistant tumors, and was associated with a reduction in the levels of circulating erythropoietin, a target of HIF-2α in blood (39). The gene discussed is EPAS1; the disease is neoplasm.